Abstract
Actualmente, el trasplante de pulmón se considera un tratamiento válido para un buen número de pacientes con insuficiencia respiratoria grave. De todas formas, las complicaciones son muy frecuentes y pueden llevar a fracaso del injerto a medio y largo plazo y menor supervivencia. De acuerdo con el registro de la International Society for Heart and Lung Transplantation, las tasas de supervivencia al primer, segundo y quinto año fueron, en 2006, del 74, 65 y 47%, respectivamente. El principal obstáculo para el éxito a largo plazo del trasplante de pulmón es el rechazo crónico, caracterizado histológicamente como bronquiolitis obliterante, que acontece en cerca de dos terceras partes de los pacientes. Uno de los factores más importantes para el desarrollo de bronquiolitis obliterante, además del número de rechazos agudos, es la infección y la enfermedad por citomegalovirus (CMV). Recientemente, se ha destacado el papel de la infección por diferentes virus respiratorios como factores de riesgo para el desarrollo de rechazo crónico en receptores de un trasplante de pulmón. Las complicaciones infecciosas son una causa frecuente de morbimortalidad en este tipo de pacientes, y la causa de muerte de cerca de la mitad de ellos. La infección bacteriana es la complicación más frecuente de un receptor de un trasplante de pulmón. Del total, el 35-66% son bacterianas y el 50-85% de los pacientes presentan como mínimo un episodio de infección bacteriana. La segunda causa más frecuente de infección, después de la bacteriana, es la infección por CMV. A pesar de utilizar diferentes estrategias de prevención, la incidencia sigue siendo elevada, y se sitúa alrededor del 7% el primer año postrasplante. Es el único tipo de trasplante de órgano sólido en el cual la etiología más frecuente de la infección fúngica es Aspergillus spp., a diferencia del resto, en que típicamente se deben a Candida spp. La incidencia de aspergilosis invasora se cifra en alrededor del 4%.
Palabras clave: Trasplante, Pulmón, Infección, Inmunosupresión
Abstract
Lung transplantation is now considered an established therapeutic option for patients with severe respiratory failure. Nevertheless, complications are frequent and can lead to intermediate- or long-term graft dysfunction and decreased survival. According to the registry of the International Society for Heart and Lung Transplantation, survival rates in these patients at one, two, and five years are 74%, 65%, and 47%, respectively. The main obstacle to long-term success of lung transplantation, however, is chronic rejection, which is characterized histologically as bronchiolitis obliterans and occurs in up to two-thirds of patients. One of the most important risk factors for the development of bronchiolitis obliterans, in addition to the number of previous acute rejection episodes and the incidence of persistent rejection, is cytomegalovirus infection and disease. Moreover, recent evidence has indicated a role for respiratory viruses as risk factors for the development of chronic rejection in lung transplant recipients. Infectious complications are a frequent cause of morbidity and mortality in these patients and are the cause of death in nearly half of them. Bacterial infection is the most frequent infectious complication in lung transplant patients. Among the total of infections, 35%-66% are bacterial and 50%-85% of patients present at least one episode. CMV is the second most frequent cause of infectious complications following lung transplantation. Despite the use of various preventive strategies, the risk of developing CMV disease in lung transplant recipients is over 5% during the first year. This is the only type of solid organ transplant in which the etiology of fungal infection is characteristically Aspergillus spp., in contrast to others in which infection by Candida spp. is most common. The incidence of invasive aspergillosis is about 4%.
Key words: Transplant, Lung, Infection, Immunosuppression
Bibliografía
- 1.Kawai A., Paradis I.L., Keenan R.J., Hardesty R.L., Hattler B.G., Pham S.M. Lung transplantation at the University of Pittsburgh: 1982 to 1994. Clin Transpl. 1994:111–120. [PubMed] [Google Scholar]
- 2.Knoop C., Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med. 2006;27:521–533. doi: 10.1055/s-2006-954609. [DOI] [PubMed] [Google Scholar]
- 3.Venuta F., Rendina E.A., De Giacomo T., Della R.G., Quattrucci S., Vizza C.D. Improved results with lung transplantation for cystic fibrosis. Transplant Proc. 2001;33:1632–1633. doi: 10.1016/s0041-1345(00)02622-1. [DOI] [PubMed] [Google Scholar]
- 4.Corris P.A., Christie J.D. Update in transplantation 2006. Am J Respir Crit Care Med. 2007;175:432–435. doi: 10.1164/rccm.200701-029UP. [DOI] [PubMed] [Google Scholar]
- 5.Pierson R.N., 3rd Lung transplantation: current status and challenges. Transplantation. 2006;81:1609–1615. doi: 10.1097/01.tp.0000226058.05831.e5. [DOI] [PubMed] [Google Scholar]
- 6.The Registry of the International Society for Heart and Lung Transplantation 2006 http://www.ishlt.org/
- 7.Al-Githmi I., Batawil N., Shigemura N., Hsin M., Lee T.W., He G.W. Bronchiolitis obliterans following lung transplantation. Eur J Cardiothorac Surg. 2006;30:846–851. doi: 10.1016/j.ejcts.2006.09.027. [DOI] [PubMed] [Google Scholar]
- 8.Knoop C., Estenne M. Acute and chronic rejection after lung transplantation. Semin Respir Crit Care Med. 2006;27:521–533. doi: 10.1055/s-2006-954609. [DOI] [PubMed] [Google Scholar]
- 9.Whitehead B., Rees P., Sorensen K., Bull C., Higenbottam T.W., Wallwork J. Incidence of obliterative bronchiolitis after heart-lung transplantation in children. J Heart Lung Transplant. 1993;12:903–908. [PubMed] [Google Scholar]
- 10.Bando K., Paradis I.L., Komatsu K., Konishi H., Matsushima M., Keena R.J. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg. 1995;109:49–57. doi: 10.1016/s0022-5223(95)70419-1. [DOI] [PubMed] [Google Scholar]
- 11.Tikkanen J.M., Kallio E.A., Bruggeman C.A., Koskinen P.K., Lemström K.B. Prevention of cytomegalovirus infection-enhanced experimental obliterative bronchiolitis by antiviral prophylaxis or immunosuppression in rat tracheal allografts. Am J Respir Crit Care Med. 2001;164:672–679. doi: 10.1164/ajrccm.164.4.2008058. [DOI] [PubMed] [Google Scholar]
- 12.Winter J.B., Gouw A.S., Groen M., Wildevuur C., Prop J. Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation. 1994;57:418–422. doi: 10.1097/00007890-199402150-00018. [DOI] [PubMed] [Google Scholar]
- 13.Kaiser L., Aubert J.D., Pache J.C., Deffernez C., Rochat T., Garbino J. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174:1392–1399. doi: 10.1164/rccm.200604-489OC. [DOI] [PubMed] [Google Scholar]
- 14.Kumar D., Erdman D., Keshavjee S., Peret T., Tellier R., Hadjiliadis D. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031–2036. doi: 10.1111/j.1600-6143.2005.00971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Khalifah A.P., Hachem R.R., Chakinala M.M., Schechtman K.B., Patterson G.A., Schuster D.P. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170:181–187. doi: 10.1164/rccm.200310-1359OC. [DOI] [PubMed] [Google Scholar]
- 16.Billings J.L., Hertz M.I., Savik K., Wendt C.H. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21:559–566. doi: 10.1016/s1053-2498(01)00405-3. [DOI] [PubMed] [Google Scholar]
- 17.Vilchez R.A., Dauber J., Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection – myth or reality? Am J Transplant. 2003;3:245–249. doi: 10.1034/j.1600-6143.2003.00056.x. [DOI] [PubMed] [Google Scholar]
- 18.Gavaldà J., Román A., Pahissa A. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Bowden R., Ljungman P., Paya C.V., editors. Transplant infections. 2nd ed. Lippincott, Williams & Wilkins; Philadelphia: 2003. pp. 62–85. [Google Scholar]
- 19.Read R.C., Shankar S., Rutman A., Feldman C., Yacoub M., Cole P.J. Ciliary beat frequency and structure of recipient and donor epithelia following lung transplantation. Eur Respir J. 1991;4:796–801. [PubMed] [Google Scholar]
- 20.Shankar S., Fulsham L., Read R.C., Theodoropoulos S., Cole P.J., Madden B. Mucociliary function after lung transplantation. Transplant Proc. 1991;23:1222–1223. [PubMed] [Google Scholar]
- 21.Herve P., Silbert D., Cerrina J., Simonneau G., Dartevelle P. Impairment of bronchial mucociliary clearance in long-term survivors of heart/lung and double-lung transplantation. The Paris-Sud Lung Transplant Group. Chest. 1993;103:59–63. doi: 10.1378/chest.103.1.59. [DOI] [PubMed] [Google Scholar]
- 22.Paradis I.L., Marrari M., Zeevi A., Duquesnoy R.J., Griffith B.P., Hardesty R.L. HLA phenotype of lung lavage cells following heart-lung transplantation. J Heart Transplant. 1985;4:422–425. [PubMed] [Google Scholar]
- 23.Dromer C., Nashef S.A., Velly J.F., Martigne C., Couraud L. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924–927. [PubMed] [Google Scholar]
- 24.Miller R.A., Lanza L.A., Kline J.N., Geist L.J. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med. 1995;152:374–376. doi: 10.1164/ajrccm.152.1.7599848. [DOI] [PubMed] [Google Scholar]
- 25.Ridgeway A.L., Warner G.S., Phillips P., Forshag M.S., McGiffin D.C., Harden J.W. Transmission of Mycobacterium tuberculosis to recipients of single lung transplants from the same donor. Am J Respir Crit Care Med. 1996;153:1166–1168. doi: 10.1164/ajrccm.153.3.8630561. [DOI] [PubMed] [Google Scholar]
- 26.Bravo C., Roldán J., Román A., Degracia J., Majo J., Guerra J. Tuberculosis in lung transplant recipients. Transplantation. 2005;79:59–64. doi: 10.1097/01.tp.0000147784.53188.dc. [DOI] [PubMed] [Google Scholar]
- 27.Roberts S.A., Franklin J.C., Mijch A., Spelman D. Nocardia infection in heart-lung transplant recipients at Alfred Hospital, Melbourne, Australia, 1989-1998. Clin Infect Dis. 2000;31:968–972. doi: 10.1086/318150. [DOI] [PubMed] [Google Scholar]
- 28.Husain S., McCurry K., Dauber J., Singh N., Kusne S. Nocardia infection in lung transplant recipients. J Heart Lung Transplant. 2002;21:354–359. doi: 10.1016/s1053-2498(01)00394-1. [DOI] [PubMed] [Google Scholar]
- 29.Aguado J.M., Herrero J.A., Gavaldá J., Torre-Cisneros J., Blanes M., Rufi G. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation. 1997;63:1278–1286. doi: 10.1097/00007890-199705150-00015. [DOI] [PubMed] [Google Scholar]
- 30.Cahill B.C., Hibbs J.R., Savik K., Juni B.A., Dosland B.M., Edin-Stibbe C. Aspergillus airway colonization and invasive disease after lung transplantation. Chest. 1997;112:1160–1164. doi: 10.1378/chest.112.5.1160. [DOI] [PubMed] [Google Scholar]
- 31.Paradowski L.J. Saprophytic fungal infections and lung transplantation - Revisited. J Heart Lung Transplant. 1997;16:524–531. [PubMed] [Google Scholar]
- 32.Westney G.E., Kesten S., De Hoyos A., Chapparro C., Winton T., Maurer J.R. Aspergillus infection in single and double lung transplant recipients. Transplantation. 1996;61:915–919. doi: 10.1097/00007890-199603270-00013. [DOI] [PubMed] [Google Scholar]
- 33.Kramer M.R., Denning D.W., Marshall S.E., Ross D.J., Berry G., Lewiston N.J. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Resp Dis. 1991;144:552–556. doi: 10.1164/ajrccm/144.3_Pt_1.552. [DOI] [PubMed] [Google Scholar]
- 34.Ruiz I., Gavaldá J., Monforte V., Len O., Román A., Bravo C. Donorto-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant. 2006;1:178–182. doi: 10.1111/j.1600-6143.2005.01145.x. [DOI] [PubMed] [Google Scholar]
- 35.Flume P.A., Egan T.M., Paradowski L.J., Detterbeck F.C., Thompson J.T., Yankaskas J.R. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med. 1994;149:1601–1607. doi: 10.1164/ajrccm.149.6.7516251. [DOI] [PubMed] [Google Scholar]
- 36.Doull I.J. Recent advances in cystic fibrosis. Arch Dis Child. 2001;85:62–66. doi: 10.1136/adc.85.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Husain S., Paterson D.L., Studer S., Pilewski J., Crespo M., Zaldonis D. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant. 2006;6:3008–3016. doi: 10.1111/j.1600-6143.2006.01548.x. [DOI] [PubMed] [Google Scholar]
- 38.Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R. Posaconazole or fluconazole for prophylaxis in severe graft-versus- host disease. N Engl J Med. 2007;356:335–347. doi: 10.1056/NEJMoa061098. [DOI] [PubMed] [Google Scholar]
- 39.Duncan A.J., Dummer J.S., Paradis I.L., Dauber J.H., Yousem S.A., Zenati M.A. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638–644. [PubMed] [Google Scholar]
- 40.Ettinger N.A., Bailey T.C., Trulock E.P., Storch G.A., Anderson D., Raab S. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis. 1993;147:1017–1023. doi: 10.1164/ajrccm/147.4.1017. [DOI] [PubMed] [Google Scholar]
- 41.Soghikian M.V., Valentine V.G., Berry G.J., Patel H.R., Robbins R.C., Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881–887. [PubMed] [Google Scholar]
- 42.Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–1097. doi: 10.1086/339329. [DOI] [PubMed] [Google Scholar]
- 43.Torre-Cisneros J., Fortún J., Aguado J.M., De la Cámara R., Cisneros J.M., Gavaldá J. Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients. Enferm Infecc Microbiol Clin. 2005;23:424–437. doi: 10.1157/13078802. [DOI] [PubMed] [Google Scholar]
- 44.Limaye A.P., Raghu G., Koelle D.M., Ferrenberg J., Huang M.L., Boeckh M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–27. doi: 10.1086/338143. [DOI] [PubMed] [Google Scholar]
- 45.Sharples L., McNeil K., Stewart S., Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271–281. doi: 10.1016/s1053-2498(01)00360-6. [DOI] [PubMed] [Google Scholar]
- 46.Holt N.D., Gould F.K., Taylor C.E., Harwood J.F., Freeman R., Healy M.D. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16:416–419. [PubMed] [Google Scholar]
- 47.Raj R., Frost A.E. Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients. J Heart Lung Transplant. 2005:671–679. doi: 10.1016/j.healun.2004.04.011. [DOI] [PubMed] [Google Scholar]
- 48.Kumar D., Erdman D., Keshavjee S., Peret T., Tellier R., Hadjiliadis D. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5:2031–2036. doi: 10.1111/j.1600-6143.2005.00971.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Milstone A.P., Brumble L.M., Barnes J., Estes W., Loyd J.E., Pierson R.N., 3rd A single-season prospective study of respiratory viral infections in lung transplant recipients. Eur Respir J. 2006;28:131–137. doi: 10.1183/09031936.06.00105505. [DOI] [PubMed] [Google Scholar]
- 50.Wendt C.H., Fox J.M., Hertz M.I. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14:479–485. [PubMed] [Google Scholar]
- 51.Glanville A.R., Scott A.I., Morton J.M., Aboyoun C.L., Plit M.L., Carter I.W. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24:2114–2119. doi: 10.1016/j.healun.2005.06.027. [DOI] [PubMed] [Google Scholar]
- 52.McCurdy L.H., Milstone A., Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22:745–753. doi: 10.1016/s1053-2498(02)00569-7. [DOI] [PubMed] [Google Scholar]
- 53.Soghikian M.V., Valentine V.G., Berry G.J., Patel H.R., Robbins R.C., Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant. 1996;15:881–887. [PubMed] [Google Scholar]
- 54.Hertz M.I., Jordan C., Savik S.K., Fox J.M., Park S., Bolman R.M., 3rd Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 1998;17:913–920. [PubMed] [Google Scholar]
- 55.Zamora M.R., Nicolls M.R., Hodges T.N., Marquesen J., Astor T., Grazia T. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635–1642. doi: 10.1111/j.1600-6143.2004.00571.x. [DOI] [PubMed] [Google Scholar]
- 56.Einsele H., Hebart H. CMV-specific immunotherapy. Hum Immunol. 2004;65:558–564. doi: 10.1016/j.humimm.2004.02.003. [DOI] [PubMed] [Google Scholar]